NEWS

Sep. 2021

Clearmind Medicine Partners with The Hebrew University to Develop Novel Psychedelic Drug

Professors Dmitry Tsvelikhovsky, Masha Niv and Avi Priel, will work together to design novel  synthetic psychedelic compounds

Psilocybin-Mushrooms-Effects-Legality-Drug-Classificatio-w.webp

2021 - 2022

Contract signed with Clearmind Medicine Inc. 

Psychedelic drug development company Clearmind Medicine Inc. will fund a study for development of novel psychedelic drugs. ( about Clearmind)

Clearmind

Psychedelic Drug Company 

Screen Shot 2021-07-22 at 9.33_edited.jpg
active%20receptor_edited.jpg

2018-2022

Israel Science Foundation (ISF) grant award

The research funds were awarded for the period of 2018-2022. Project: Stretching the Model of TRPV1 Activation.

 Israel Science Foundation (ISF)

download-1.png
Picture2_edited.png

2021 - 2022

Israel Innovation Authority 

Bio-convergence grant award

The research funds were awarded for the period of 2021-22. Project: Development of Novel Neurotropic Drug for Polyneuropathy.

רשות החדשנות

Israel Innovation Authority

%D7%A8%D7%A9%D7%95%D7%AA%20%D7%9C%D7%97%
toxins-09-00326-g001_edited.jpg

2017 - 2018

"Nofar" Ministry of Science and Industry grant awarded

The research funds were awarded for the period of 2017-18. Project: Novel Synthetic Scaffold DT100 Promotes Silencing of the Pain Receptor TRPV1.

Ministry of Economy and Industry

ITC-Logo-Sydney-Australia-with-MoE_edite
Marijuana-Plant.jpg

2019 - 2020

Contract signed with Scopus Biopharma (about Scopus)  

The Scopus Biopharma company  funded the conduct of a feasibility study for the development of protocols for synthesis of new CBD derivatives.

Multidisciplinary Center for Cannabinoid Research 

1_new_edited_edited_edited.png
Science Class

2014 - 2018

Volkswagen Stiftung grant award

Structure Pattern Recognition: A Catalyst for Methodology Development in Total Synthesis. Cooperation Lower Saxony - Israel.

Volkswagen Foundation

VolkswagenFoundation.jpg